Advertisement
HOLON, Israel, Aug. 15, 2019 /PRNewswire/ -- Estar Technologies Ltd. (Estar Medical) announced today that Regenlab failed to pay legal costs resulting from two orders made by the UK High Court (Patent Court). The Patent Court awarded Estar Medical extensive legal costs after it revoked the Regenlab PRP patent in its entirety. Regenlab claims it is unable to pay the ordered costs because its access to cashflow is "very limited" and a "restricted amount of liquid funds available". Regenlab originally asked the Patent Court, in a witness statement submitted by its legal counsel, Mr. Andreas Pigni, to defer the payment which "could have a 'domino effect' on the viability of [its] business" and "would impact on Regen's business in a way that would be difficult to quantify financially but is likely to be substantial and would take significant time for Regen to recover its position".
The Patent Court judgment is in line with the decision of the Opposition Division of the European Patent Office (EPO) which also revoked Regenlab PRP patent in its entirety for lack of novelty and added mater. The EPO and UK judgments add to Estar Medical's winning the infringement claim in Germany last year and the venue judgment in Federal Court in New York in which Regenlab also lost against Estar Medical.
About Estar Medical Estar Medical is a leading innovator of medical devices in the biologics, cell therapy and platelet rich plasma fields which it markets under the well-recognized TROPOCELLS®, CELLENIS® and other related brands. Estar Medical has developed a unique and effective technology for the simple preparation of PRP by enabling the physician to easily and effectively separate and concentrate growth factors taken from the patient's own blood for the purpose of building new tissues and effectively accelerate the natural autologous wound healing process. Estar Medical remains committed to providing innovative proprietary products of the highest quality and safety, as well as protecting its partners, distributors and global clients through enforcement of its intellectual property rights.
For more information visit: www.estar-medical.com
Contact: Ilana Allesh, Head of Marketing [email protected]
Advertisement
The Patent Court judgment is in line with the decision of the Opposition Division of the European Patent Office (EPO) which also revoked Regenlab PRP patent in its entirety for lack of novelty and added mater. The EPO and UK judgments add to Estar Medical's winning the infringement claim in Germany last year and the venue judgment in Federal Court in New York in which Regenlab also lost against Estar Medical.
About Estar Medical Estar Medical is a leading innovator of medical devices in the biologics, cell therapy and platelet rich plasma fields which it markets under the well-recognized TROPOCELLS®, CELLENIS® and other related brands. Estar Medical has developed a unique and effective technology for the simple preparation of PRP by enabling the physician to easily and effectively separate and concentrate growth factors taken from the patient's own blood for the purpose of building new tissues and effectively accelerate the natural autologous wound healing process. Estar Medical remains committed to providing innovative proprietary products of the highest quality and safety, as well as protecting its partners, distributors and global clients through enforcement of its intellectual property rights.
For more information visit: www.estar-medical.com
Contact: Ilana Allesh, Head of Marketing [email protected]
View original content:http://www.prnewswire.com/news-releases/estar-medical-regenlab-is-in-breach-of-uk-court-orders-following-revocation-of-its-prp-patent-300902320.html
SOURCE Estar Technologies Ltd.
